Výsledky vyhledávání

Akademický článek

Evaluation of the clinical impact of bone marrow cultures in current medical practice

Autor: Gal Sharvit, Daniel Schwartz, Gabriel Heering, Alexander Shulman, Abraham Avigdor, Galia Rahav, Amos Toren, Arnon Nagler, Jonathan Canaani

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)

Abstract The clinical yield and benefit of performing bone marrow cultures for various clinical indications has been challenged and their clinical necessity remains debatable. We sought to assess the clinical yield and benefit of performing routine b

Externí odkaz: https://doaj.org/article/a69132e642354dafa5896661b6c39ff8

Zobrazit plný text záznamu

Plný text ve formátu HTML

ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy

Autor: Naama Keren-Froim, Gabriel Heering, Gal Sharvit, Maya Zlotnik, Arnon Nagler, Avichai Shimoni, Abraham Avigdor, Jonathan Canaani

Publikováno v: Annals of Hematology. 101:309-316

Early mortality remains a challenging therapeutic facet of the initial induction phase of intensive chemotherapy in patients with acute myeloid leukemia (AML). The impact of standard molecular evaluation and risk category of the European LeukemiaNet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4146924c1d777147e5c6f06adaedc8
https://doi.org/10.1007/s00277-021-04716-4

Zobrazit plný text záznamu

Assessing data gathering of chatbot based symptom checkers - a clinical vignettes study

Autor: Niv Ben-Shabat, Gal Sharvit, Ben Meimis, Daniel Ben Joya, Ariel Sloma, David Kiderman, Aviv Shabat, Avishai M Tsur, Abdulla Watad, Howard Amital

Publikováno v: International Journal of Medical Informatics. 168:104897

The burden on healthcare systems is mounting continuously owing to population growth and aging, overuse of medical services, and the recent COVID-19 pandemic. This overload is also causing reduced healthcare quality and outcomes. One solution gaining

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef6edef76ba86b4f12498736f2e3869a
https://doi.org/10.1016/j.ijmedinf.2022.104897

Zobrazit plný text záznamu

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

Autor: Arnon Nagler, Jonathan Canaani, Gal Sharvit, Abraham Avigdor, Gabriel Heering, Maya Zlotnik, Avichai Shimoni, Drorit Merkel

Publikováno v: Clinical lymphoma, myelomaleukemia. 22(2)

Achievement of initial remission remains the most important clinical factor predicting long term survival in acute myeloid leukemia (AML) patients treated with intensive chemotherapy. Yet, whether the patient subset in need of a second cycle of inten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::422c25ef2d4e99e964d985e964201113
https://pubmed.ncbi.nlm.nih.gov/34593360

Zobrazit plný text záznamu

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Autor: Avichai Shimoni, Jonathan Canaani, Arnon Nagler, Abraham Avigdor, Naama Keren Froim, Gal Sharvit, Maya Zlotnick, Gabriel Heering

Publikováno v: Blood. 138:3392-3392

Background. Early mortality remains a challenging therapeutic facet of the initial induction phase of intensive chemotherapy in patients with acute myeloid leukemia (AML). The impact of standard molecular evaluation and risk category of the European

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22cd2651e26fc0eece0edfd8a6b61281
https://doi.org/10.1182/blood-2021-145551

Zobrazit plný text záznamu

Autor: Gal Sharvit, Gabriel Heering, Maya Zlotnick, Arnon Nagler, Abraham Avigdor, Avichai Shimoni, Jonathan Canaani

Publikováno v: Blood. 138:3390-3390

Background: Achievement of initial remission remains the most important clinical factor predicting long term survival in acute myeloid leukemia (AML) patients treated with intensive chemotherapy. Yet, whether the patient subset in need of a second cy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9160fe5a30e1739303a32e461ef58500
https://doi.org/10.1182/blood-2021-145552

Zobrazit plný text záznamu